Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, discuss treatment approaches for multiple myeloma using example patient cases.
Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California
Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California
Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
Nantes, France
Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain
This program has been made available online.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Expert case-based text module on managing toxicities with BCL-2 and PI3K inhibitors in CLL, from Clinical Care Options (CCO)
Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)
Clinical Care Options (CCO): Expert review of key data in MDS and MPN from the 2021 ASH annual meeting
Clinical Care Options (CCO): Experts John M. Burke, MD, and Peter Martin, MD, review key data in lymphomas and CLL presented at the 2021 American Society of Hematology Annual Meeting
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.